Compare Amgen, Inc. (AMGN) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vertiv Holdings Co — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Vertiv Holdings Co trades at $306.89 (market cap $122.48B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | VRT | |
|---|---|---|
Market Cap | $196.12B | $122.48B |
Sector | Health | Technology |
52-Week High | $388.16 | $376.23 |
52-Week Low | $271.18 | $121.82 |
Enterprise Value | $241.41B | $123.24B |
Dividend Yield | 2.77% | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $360.45, down 0.81% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly EPS beats. Revenue grew to $36.75B in 2025 with a net income margin of 20.96%, though high debt levels and recent regulatory challenges for Tavneos in Europe present headwinds. Analyst sentiment is positive with 57.9% buy ratings and a consensus price target of $351.29.
The outlook for AMGN is cautiously optimistic, supported by earnings momentum and a diversified product portfolio, but investors face risks from patent expirations, competitive biosimilar pressures, and regulatory setbacks. The stock's current price near consensus target suggests limited near-term upside, requiring careful monitoring of pipeline developments and debt management.
Vertiv Holdings (VRT) trades at $318.86, down 1.56% amid recent volatility, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals with support at $315 and resistance at $323, while valuation metrics remain elevated with P/E of 80.12. Recent expansion in Malaysia supports AI infrastructure growth as the company benefits from strong data center demand and a $15 billion backlog.
VRT presents a compelling growth story with 94.7% analyst buy ratings and a $395.23 consensus target, representing 24% upside. However, premium valuation and competitive pressures from nVent Electric pose risks. The AI infrastructure theme provides strong tailwinds, but investors should monitor execution on the substantial backlog and margin sustainability amid expansion efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
